Sino Biopharmaceutical (HK:1177) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical has entered into a global collaboration with Biosion and Aclaris Therapeutics to develop an anti-TSLP monoclonal antibody, BSI-045B. Aclaris will pay over $40 million in cash and 19.9% in common stock to Sino Biopharmaceutical, alongside potential regulatory and sales milestone payments exceeding $900 million. This strategic partnership aims to advance treatments for conditions such as asthma and atopic dermatitis.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.